Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577877 | 0.92 | ALDH1A1 (0.49) | MEN1KMT2AMCHR1ALDH1A1PKM | |
| SCHEMBL5577744 | 0.89 | ABCB1 (0.49) | MCHR1ALDH1A1 | |
| SCHEMBL5577622 | 0.88 | MEN1 (0.60) | MEN1KMT2AMCHR1ALDH1A1PKM | |
| SCHEMBL5577316 | 0.84 | DRD2 (0.64) | MEN1KMT2AMCHR1KCNH2CACNA1I | |
| SCHEMBL5577272 | 0.84 | DRD2 (0.48) | MEN1KMT2AMCHR1ALDH1A1PKM | |
| SCHEMBL5577770 | 0.84 | MEN1 (0.53) | MEN1KMT2AMCHR1ALDH1A1PKM | |
| SCHEMBL5577360 | 0.83 | MCHR1 (0.60) | MEN1KMT2AMCHR1KCNH2CACNA1I | |
| SCHEMBL5577650 | 0.83 | MEN1 (0.62) | MEN1KMT2AMCHR1ALDH1A1KCNH2 | |
| SCHEMBL5577876 | 0.81 | ALDH1A1 (0.65) | MEN1KMT2AMCHR1ALDH1A1KCNH2 | |
| SCHEMBL5577675 | 0.81 | TSHR (0.66) | MEN1KMT2AMCHR1HDAC1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MEN1 748/4885KMT2A 3527/4885MCHR1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.